A total of 303 patients with ALK IHC-positive NSCLC were reevaluated in the ALEX trial study, of which 203 were FISH-positive, 39 were FISH-negative, and 61 were FISH-uninformative, and the corresponding ORR was 90.6, 28.6, and 96%, respectively (9). The gene discussed is ALK; the disease is non-small cell lung carcinoma.